Our previous studies have demonstrated that Aquaporin 1 (AQP1) is overexpressed in breast cancer. However, the mechanism remains elusive. MicroRNA 320 (miR-320) downregulation has been reported in various types of cancers, and it may regulate AQP1 expression. In this study, miR-320 and AQP1 expressions were investigated by quantitative reverse transcription-PCR, in situ hybridization, and immunohistochemistry. The clinicopathological implications of these molecules were also analyzed. We found that miR-320 expression is downregulated in both plasma and tumor tissue in human breast cancer patients. Survival analysis showed that reduced expression of miR-320 and overexpression of AQP1 are associated with worse prognosis. Luciferase assays showed that miR-320 negatively regulates AQP1 expression. In addition, cell proliferation, migration, and invasion assays were performed to investigate the effects of miR-320 on breast cancer cells. Our results showed that miR-320 overexpression inhibits cell proliferation, migration, and invasion in breast cancer cells by downregulating AQP1. These observations suggested that miR-320 downregulation may enhance AQP1 expression in breast cancer, favoring tumor progression. Our findings indicated that miR-320 and AQP1 may serve as prognostic biomarkers and therapeutic targets in the treatment of breast cancer.
Introduction
Breast cancer is the most common cancer and the second leading cause of cancer death among women worldwide [1] . Despite standard treatment strategies, including surgical resection followed by radiation and/or chemotherapy, prognosis remains unsatisfactory [2, 3] . Early detection may still be the key to improve patient survival, particularly if more sensitive and specific diagnostic markers are developed. Therefore, further study on the pathogenesis is critical for the early diagnosis and treatment of breast cancer.
Uncontrolled cell proliferation, invasion, and migration play a central role in breast carcinogenesis. Aquaporin 1 (AQP1), a waterselective transport protein in cell membranes, plays a key role in tissue environment homeostasis and cell migration [4] . The role of AQP1 in human carcinogenesis has recently become an area of great interest. AQP1 overexpression has been reported in a variety of human malignancies, including tumors of the brain, colon, and lung, and is associated with uncontrolled cell replication, invasion, migration, and tumor metastasis [5] [6] [7] . Our previous study revealed that AQP1 is overexpressed in breast cancer tissues compared with normal breast tissues [8] . However, the functional role of AQP1 and the detailed mechanism of its overexpression in breast cancer are not yet fully understood.
MicroRNAs (miRNAs) are a class of tiny, noncoding RNA molecules that post-transcriptionally regulate gene expression by either directly degrading mRNA or indirectly repressing protein translation [9] . miRNAs regulate numerous physiological and pathological processes such as cell proliferation, development, cancer progression, stem cell self-renewal, and differentiation [10, 11] . Recent studies have revealed that miRNAs can function as tumor suppressors or oncogenes, and abnormal miRNA expression is associated with a variety of human cancers [12] [13] [14] .
To obtain a deeper understanding of the molecular mechanism of AQP1 in tumorigenesis, we searched for miRNAs that regulate AQP1 expression, using miRNA target prediction algorithms. Our results showed that miR-320 is a key candidate miRNA, with a binding site in the 3′-untranslated region (UTR) of AQP1. Recent studies have shown that miR-320 is significantly downregulated in multiple types of cancers, including colon cancer, breast cancer, acute myelogenous leukemia, and cervical cancer [15] [16] [17] [18] [19] . However, the expression patterns and biological roles of miR-320 and its target gene AQP1 in breast cancer have not yet been clearly elucidated.
Materials and Methods

Patients and clinical samples
This study included 48 patients with breast cancer that was confirmed by histopathological analysis at the Department of Breast Surgery, Wuxi Maternity and Child Health Care Hospital, affiliated to Nanjing Medical University (Wuxi, China), from May 2007 to March 2008, with consent from all patients and approval by the Ethics Committee of Nanjing Medical University (Nanjing, China). The experiment was carried out in accordance with the Code of Ethics of the World Medical Association. The clinicopathological characteristics of the breast cancer patients are summarized in Table 1 . None of the patients had previously received radiotherapy, chemotherapy, or other treatment before surgery. After surgical removal, 48 breast cancer tissues and their corresponding adjacent normal breast tissues were formalin-fixed and paraffin-embedded for histopathological diagnosis, in situ hybridization (ISH), and immunohistochemistry (IHC). For quantitative reverse transcription-PCR (qRT-PCR) and western blot analysis, fresh tissue samples (20 breast cancer tissues and their corresponding adjacent normal breast tissues) were immediately frozen in liquid nitrogen until further use. About 2 ml plasma was isolated from 5 ml whole blood (20 breast cancer patients and 20 normal control populations) by centrifugation at 2000 rpm for 5 min, and then stored at −80°C.
qRT-PCR analysis
The expression levels of mature miR-320 and AQP1 mRNA were determined by qRT-PCR [20] . The extraction of total RNA from plasma (20 breast cancer patients and 20 normal control populations) and tissues (20 breast cancer tissues and their corresponding adjacent normal breast tissues) was performed according to a previously described method [19] using Trizol reagent (Invitrogen, Carlsbad, USA). Complementary DNAs (cDNAs) were synthesized using 1 μg of total RNA and Prime Script TM RT reagent kit (TaKaRa, Dalian, China). For miR-320 detection, TaqMan microRNA assays (Applied Biosystems, Foster City, USA) were used and small nuclear RNA U6 was used as the normalization control. AQP1 mRNA was quantified by qRT-PCR using SYBR Premix Ex Taq (TaKaRa). β-actin was used as an internal control. Primers were as follows: for miR-320, 5′-ACACTCCAGC TGGGAAAAGCTGGGTTGAGA-3′ (F) and 5′-TGGTGTCGTGGAG TCG-3′ (R); for AQP1, 5′-GACCCGCTCGGACTTACT-3′ (F) and 5′-CTTCTGGACCCATGCTGT-3′ (R). Relative quantifications of miR-320 and AQP1 mRNA expression were performed using the 2 −ΔΔCT method [21] .
In situ hybridization
ISH was performed as previously described [19] . The slides were treated according to the manufacturer's instructions, and hybridized with 10 pmol locked nucleic acid (LNA)-modified and digoxigenin (DIG)-oligonucleotide probe (Exiqon A/S, Vedbaek, Denmark) complementary to miR-320. After incubation with anti-DIG-HRP Fab fragments conjugated to horseradish peroxidase, the hybridized probes were detected by incubation with 3′3-diaminobenzidine solution and the nuclei were counterstained with Carazzi's hematoxylin. The stained sections were categorized into two semi-quantitative grades based on the percentages of positive tumor cells: negative (≤5% positive cells) or positive (6%−100% positive cells) [22] .
Immunohistochemistry analysis
IHC was performed as previously described using an anti-AQP1 antibody (diluted 1:200, ab9566; Abcam, Cambridge, USA) [6] . Brown staining of the membrane was considered positive. The distribution of miR-320 expression was assessed by in situ hybridization (ISH). AQP1 expression was assessed by immunohistochemistry (IHC). miR-320 expression was significantly lower than AQP1 expression, which was significantly higher in breast cancer tissues than in adjacent normal controls. *P = 0.023 and **P = 0.037. positive cells was graded as follows in a blinded method: 0 = no detectable staining; 1 = staining <1/3 positive cells; 2 = staining 1/3−2/3 positive cells; and 3 = staining >2/3 positive cells. The intensity of staining was graded as follows: 0 = no signal; 1 = weak; 2 = moderate; and 3 = strong staining. The scores for distribution and intensity were added and graded as follows: 0 = (−); 2, 3 = (±); 4 = (+); 5 = (++); 6 = (+++). Scores <4 were defined as negative and scores >4 were defined as positive [8] .
Luciferase assays
Wild-type (WT) AQP1-3′-UTR was amplified by PCR from human cDNA using the following primers: F: 5′-TGTAGACACAGGTCA CCATTATG-3′ and R: 5′-CAAAGCTGATCCTGATCTCTGA-3′. The mutant (mut) Mcl-1-3′-UTR was amplified using the following primers: F: 5′-TGTAGACACAGGTCACCATTATG-3′ and R: 5′-CT ATGGTCATCCTGATCTCTGA-3′. The DNA segments produced from these amplifications were inserted into the pMIR-REPORT miRNA Expression Reporter Vector (Ambion, Carlsbad, USA) using the SacI and HindIII sites. Human breast cancer cells (MCF-7) was purchased from Cell Bank of Shanghai Institutes for Biological Sciences (Shanghai, China). The cells were cultured in 24-well plates and co-transfected with pMIR-REPORT vectors containing either the WT or the mutated AQP1-3′-UTR segments along with the control vector, Renilla luciferase reporter vector (PGL4.74), using Lipofectamine 2000 (Invitrogen). These MCF-7 cells were co-transfected with the miR-320 mimics (F: 5′-AAAAGCUGGGUUGAGAGGGCGA-3′ and R: 5′-GCCC UCUCAACCCAGCUUUUUU-3′) and negative control (NC; F: 5′-UUC UCCGAACGUGUCACGUdTdT-3′ and R: 5′-ACGUGACACGUUC GGAGAAdTdT-3′) constructed by GenePharma (Shanghai, China) using Lipofectamine 2000 according to the manufacturer's instructions. Luciferase assays were performed 48 h after transfection using a dual luciferase reporter assay kit (Promega, Madison, USA). Renilla luciferase activity was used to normalize the transfection efficiency. Three independent experiments were performed in triplicate.
Cell culture and transfection MCF-7 cells were cultured in RPMI 1640 medium supplemented with 10% charcoal-stripped fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin (Sigma-Aldrich, St Louis, USA) under a humidified 5% CO 2 /95% air atmosphere at 37°C. After reaching 90% confluence, cells were trypsinized and passaged. The cells were seeded in 6-well plates at a density of 2 × 10 5 cells per well and treated after overnight culture. MCF-7 cells were transfected with either miR-320 mimics or NC precursor using Lipofectamine 2000 according to the manufacturer's instructions.
Cell proliferation, migration, and invasion assays
For the cell proliferation assays, a total of 2 × 10 3 MCF-7 cells per well were seeded into wells of 96-well plates and transfected with miR-320 mimics and NC for 24 h. Cell proliferation was measured using a CCK8 kit (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. Cell migration and invasion assays were performed using a Transwell assay kit (Corning Co., Corning, USA). After transfection with miR-320 mimics and NC for 24 h as described above, MCF-7 cells (1 × 10 4 cells/100 μl serum-free medium) were placed into the upper chamber. Basal medium supplemented with 5% FBS (600 μl) was placed into the lower chamber. Chambers were assembled and kept at 37°C in 5% CO 2 for 12 h (for the migration assay) or 24 h (for the invasion assay). After incubation, cells from the upper surface of the Millipore membranes (Billerica, USA) were removed, and the migrated cells on the lower surface of the membranes were fixed and stained with crystal violet and counted in three randomly selected fields under a microscope. Representative images were obtained using a DP Controller digital camera system. For the invasion assay, the upper chambers were pre-incubated with Matrigel for 3 h to form a layer of Matrigel, and the migrated cells in the lower chamber were counted 24 h after plating. These assays were performed in triplicate and repeated for three times.
Western blot analysis
Tissues and cells were homogenized with an Ultra Turrax homogenizer (Ika, Petaling Jaya, Malaysia) in lysis buffer as previously described [19] . The protein extracts were separated by SDSpolyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes. After block with blocking buffer, membranes were incubated with specific primary antibodies, anti-AQP1 (1:500; Abcam) or anti-tubulin (1:1000; Abcam), followed by incubation with corresponding HRP-conjugated secondary antibody. Specific protein bands were detected using an ECL kit and AlphaImager (FluorChem5500; Alpha Innotech, San Leandro, USA). Protein expression levels were analyzed using AlphaEaseFC software (Alpha Innotech).
Statistical analysis
Statistical analyses were performed using Statistical Program for Social Sciences (SPSS) software v.16.0 (SPSS, Chicago, USA). Pairedsample t-tests were used to compare miR-320 and AQP1 mRNA expression levels between breast cancer tissues and adjacent normal breast tissues. The associations between miR-320 and AQP1 expressions and clinicopathological features were analyzed using the Chisquare test. The correlation between miR-320 and AQP1 mRNA expressions in breast cancer was assessed using Spearman's correlation test. Kaplan-Meier curves were constructed, and the log-rank test was performed to analyze survival data. The results are expressed as the mean ± standard error of the mean (SE). P-value < 0.05 was considered statistically significant.
Results
miR-320 expression is downregulated in both plasma and tumor tissue in human breast cancer patients
Circulating miR-320 levels were determined by qRT-PCR in 20 breast cancer patients and 20 normal subjects. Plasma miR-320 levels were markedly decreased in breast cancer patients compared with those in normal subjects (n = 20, P = 0.0019; Fig. 1A ), indicating that miR-320 is detectable in blood samples and may be a potential biomarker for breast cancer diagnosis. Additionally, miR-320 expression was significantly lower in breast cancer tissue than that in normal breast tissue (n = 20, P = 0.032; Fig. 1B ).
Expression levels and clinical significance of miR-320 and AQP1 in breast cancer
To obtain a deeper understanding of the interaction of miR-320 and AQP1 in breast cancer development, miR-320 and AQP1 expressions were investigated by ISH and IHC, respectively, in 48 pairs of breast cancer tissues and corresponding normal breast tissues. Positive brown staining in the cytoplasm indicated the relative expression levels of miR-320, and brown staining of cell membranes indicated relative AQP1 expression. Our results showed that miR-320 expression was decreased, while AQP1 expression was increased, in breast cancer tissues compared with those in normal breast tissues (Fig. 2) . In breast cancer patients, miR-320 expression was detected in only 45.83% of tissues (22 out of 48), a significantly lower detection rate of expression than that in the adjacent normal tissue controls (45.83% vs. 68.75%, P = 0.023). In contrast, AQP1 expression was detected at a significantly higher rate in breast cancer tissues than that in the adjacent normal tissue controls (50% vs. 29.17%, P = 0.037; Table 1 ). Spearman's correlation analysis indicated that miR-320 expression was negatively correlated with AQP1 expression in breast cancer patients (r = −0.389, P = 0.008; Table 2 ).
The clinical significance of miR-320 and AQP1 expressions in breast cancer was analyzed by evaluating the associations between miR-320 and AQP1 expressions in breast cancer tissues and clinicopathological parameters. As shown in Table 2 , the breast cancer specimens were divided into two groups: high expression and low expression, according to the mean percentages of miR-320 and AQP1 expression profiles. Statistical analysis showed that miR-320 expression was significantly associated with clinicopathological staging (P = 0.004) and lymph node involvement (P = 0.024). Additionally, AQP1 expression was associated with histological grade (P = 0.033). These results indicate that miR-320 and AQP1 may play important roles in the progression of breast cancer. Figure 1 . miR-320 level in plasma and tumor tissues of human breast cancer patients and normal subjects (A) miR-320 level in plasma of breast cancer patients and normal subjects. (B) miR-320 level in tumor tissues and adjacent normal tissues of breast cancer patients. miR-320 level was analyzed by qRT-PCR. miR-320 level in the plasma of breast cancer patients was downregulated compared with that in normal control subjects. miR-320 expression was downregulated in breast cancer tissues compared with that in adjacent normal tissues. Normal: normal control subjects; Patient: breast cancer patients. *P < 0.05 and **P < 0.01. Figure 2 . Expressions of miR-320 and AQP1 in human breast cancer tissues and adjacent normal tissues Immunohistochemistry (IHC) analysis showed that AQP1 protein was strongly expressed in breast cancer tissues (B), indicated by extensive brown staining of cell membranes, but expressed at barely detectable levels in adjacent normal tissues (A). In situ hybridization (ISH) analysis showed that miR-320 expression was almost absent in the majority of breast cancer tissues (D), and very high in the adjacent normal tissues, with strong brown staining in the cytoplasm (C). Normal: normal breast tissue; Tumor: breast cancer tissue. Magnification, 40×.
miR-320 and AQP1 expressions in breast cancer associated with reduced overall survival A survival analysis was performed based on available clinical follow-up information on the 48 patients. At the end of the followup period, 23 patients were still alive and 22 had died. The remaining three were lost to follow-up, resulting in an overall follow-up rate of 93.75%. The Kaplan-Meier curves for the 45 breast cancer patients revealed overall survival (Fig. 3) . A comparison of survival curves revealed that low miR-320 expression (Fig. 3A) and high AQP1 expression (Fig. 3B) in patients with breast cancer were related to reduced overall survival by log-rank tests (P = 0.041 and P = 0.038, respectively).
miR-320 negatively regulates AQP1 expression by targeting the 3′-UTR of AQP1
Our previous study showed that AQP1 is overexpressed in breast cancer tissues and participates in the pathogenesis of breast cancer [8] . However, the mechanism of AQP1 overexpression in breast cancer is unclear. To explore the molecular mechanisms of AQP1 regulation, three bioinformatic algorithms, TargetScan, PicTar, and miRanda, were applied to identify potential miRNAs involved in the regulation of AQP1. miR-320, one of the candidates indicated in our analysis, is known as an important tumor suppressor in many types of cancers [13, 19, 23 ]. An miR-320 binding site was found in the 3′-UTR of AQP1 (Fig. 4A) .
To confirm whether miR-320 regulates AQP1 expression in breast cancer cells, MCF-7 cells were transfected with either miR-320 mimics or NC precursor (control). Results showed that miR-320 overexpression significantly inhibited AQP1 expression (P < 0.05) at both the mRNA and the protein levels (Fig. 4B) . To confirm whether miR-320 regulates AQP1 expression by binding to the 3′-UTR of AQP1, two AQP1 transcription reporter vectors with or without miR-320 binding sites (WT AQP1-3′-UTR and mutant AQP1-3′-UTR) were generated. Our results showed that miR-320 significantly suppressed the luciferase activity of the WT-AQP1-3′-UTR reporter containing a miR-320 binding site, while the luciferase activity of the Mut-AQP1-3′-UTR reporter, which has no miR-320 binding site, was unaffected (Fig. 4C) . These results indicate that miR-320 negatively regulates AQP1 expression by binding to the 3′-UTR of AQP1.
miR-320 inhibits proliferation, migration, and invasion of breast cancer cells
To investigate the functional role of miR-320 in breast cancer progression, MCF-7 cells were transfected with miR-320 mimics or NC, and cell proliferation, migration, and invasion assays were performed. Our in vitro studies showed that miR-320 overexpression attenuated cell proliferation from Day 3 to Day 5 ( Fig. 5A ; P < 0.05). In addition, miR-320 significantly inhibited breast cancer cell migration and invasion ( Fig. 5B,C ; P < 0.01). These results suggest that miR-320 efficiently inhibits the proliferation, migration, and invasion of breast cancer cells, which play key roles in breast cancer tumorigenesis.
Discussion
Previous studies have demonstrated that AQP1 is involved in tumor growth, cell migration, and metastatic potential of tumor cells in vitro [7, 24, 25] . However, the functional role of AQP1 and the mechanism of its overexpression in breast cancer have not yet been clarified. Our previous studies revealed that AQP1 is upregulated in breast cancer tissues compared with that in normal tissues, suggesting that AQP1 may play an important role in the pathogenesis of breast cancer [8] . Emerging evidence indicates that miRNAs may serve as tumor suppressors or oncogenes in many cancers by regulating translational repression or targeting mRNA degradation Statistical analysis was performed by Chi-square test. *P < 0.05. [22, [26] [27] [28] [29] . However, the miRNA signature regulating AQP1 in breast cancer patients has yet to be elucidated. Recently, several studies have shown that miR-320 was downregulated in breast cancer, colon cancer, and acute myelogenous leukemia [15] [16] [17] [18] and suppressed cell proliferation in prostate cancer [18] . miR-320 expression was also found to be correlated with the probability of recurrence-free survival in colon cancer [16] . In the present study, we investigated whether miR-320 is a tumor suppressor in breast cancer, and whether circulating miR-320 is detectable and can be used as a biomarker in breast cancer patients. We first detected circulating miR-320 in human plasma samples by qRT-PCR, and our results showed that circulating miR-320 levels were significantly lower in breast cancer patients than in healthy subjects (Fig. 1A) , indicating that miR-320 can potentially serve as a novel breast cancer biomarker. We then Overexpression of miR-320 inhibits AQP1 mRNA and protein expressions. Luciferase assay was performed with luciferase reporters containing wildtype (WT) or mutant (Mut) AQP1 3′-UTR regions following co-transfection with precursors of miR-NC (negative control) or miR-320. (C) miR-320 overexpression inhibited WT, but not Mut, reporter activities, indicating significant changes in reporter activities. *P < 0.05 and **P < 0.01. miR-320 downregulation enhances AQP1 expression in breast cancer examined miR-320 expression levels in breast cancer tissues by qRT-PCR, and found that miR-320 expression was significantly lower in breast cancer tissues than that in normal tissues (Fig. 1B) .
We further demonstrated by ISH and IHC that decreased miR-320 expression was associated with increased AQP1 expression in breast cancer tissues compared with that in normal breast tissues ( Fig. 2 and Table 1 ). Spearman's correlation analysis revealed a negative correlation between miR-320 and AQP1 expression in breast cancer tissues ( Table 1 ). All these findings indicate that miR-320 expression and AQP1 expression are closely correlated with breast cancer development. To further assess the clinical significance of miR-320 and AQP1 expression in the patients, we evaluated their association with two clinicopathological parameters, including prognosis. Our results showed that reduced miR-320 expression was significantly associated with pathological stage and lymph node involvement. AQP1 overexpression was associated with the pathological grade ( Table 2 ). Survival analysis demonstrated that miR-320 downregulation combined with AQP1 overexpression was significantly associated with a poorer prognosis (Fig. 3) . These results indicate that miR-320 and AQP1 may participate in the pathogenesis of breast cancer, and could be used as new biomarkers for breast cancer diagnosis and prognosis.
In addition, we successfully predicted and verified that AQP1 is negatively regulated by miR-320 at the post-transcriptional level via its specific target site in the 3′-UTR region (Fig. 4) . To further investigate whether miR-320 is a tumor suppressor in breast cancer progression via AQP1 regulation, MCF-7 cells were transfected with miR-320 mimics or NC, and cell proliferation, migration, and invasion assays were performed. These functional analyses showed that miR-320 overexpression significantly inhibited proliferation, migration, and invasion in breast cancer cells (Fig. 5) , likely via regulation of its target gene AQP1. These results strongly indicate that miR-320 is an important tumor suppressor in breast cancer development and progression.
In conclusion, we demonstrated that decreased miR-320 expression may promote the development and progression of human breast cancer through the AQP1-mediated proliferative signaling pathway. Our findings suggest that miR-320 is a novel tumor suppressor and a negative regulator of AQP1, which may play a key role in breast carcinogenesis and serve as a reliable prognostic indicator and therapeutic target in the treatment of breast cancer. This study provides new insights into the pathophysiology of breast cancer and potential novel treatment targets. Further studies are necessary to elucidate the regulatory mechanism of miR-320 in the pathogenesis of breast cancer. The cell invasion assay shows that transfection with miR-320 mimics significantly suppressed the invasion capacity of MCF-7 cells compared with transfection with the NC. *P < 0.05 and **P < 0.01.
